ASCO Schedule

NewYork-Presbyterian at ASCO 2017

Friday, June 2

3:45-3:57 PM

Expanding the Actionable Landscape: Bladder Cancer Genomics

Bishoy Faltas | NewYork-Presbyterian & Weill Cornell Medicine

Location: Arie Crown Theater

3:45-4:05 PM

Unresectable Pancreatic Cancer: What Is the Value Added with Radiation?

John Ng | NewYork-Presbyterian & Weill Cornell Medicine

Location: S100a

4:45-5:05 PM

Health Disparities and the Global Landscape of Lymphoma Care Today

Adrienne Phillips | NewYork-Presbyterian & Weill Cornell Medicine

Location: E450ab

Saturday, June 3

8:00-11:30 AM

Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201

Diane Reidy | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

8:00-11:30 AM

Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade

Claud Grigg | NewYork-Presbyterian & Columbia University Medical Center

8:00-11:30 AM

A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma

and

Impact of early FDG-PET directed intervention on preoperative therapy for locally advanced gastric cancer: A Cooperative Group random assignment phase II study (Alliance A021302) Impac

Manish Shah | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

1:15–4:45 PM

Characterizing the tumor microenvironment (TME) in primary melanomas using multiplex immunohistochemistry (mIHC)

Robyn Gartrell | NewYork-Presbyterian & Columbia University Medical Center

1:15–4:45 PM

Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715)

Dawn Hershman | NewYork-Presbyterian & Columbia University Medical Center

1:15–4:45 PM

Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor

Kimberly Komatsubara | NewYork-Presbyterian & Columbia University Medical Center

1:15–4:45 PM

Latino ethnicity, immigrant status, and preference for life-extending end-of-life cancer care

Ana Tergas | NewYork-Presbyterian & Columbia University Medical Center

5:03-5:15 PM

Expanding Immunotherapy in Gastrointestinal Cancers

Manish Shah | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall D2

Sunday, June 4

8:00-11:00 AM

Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial

Andrew Lassman | NewYork-Presbyterian & Columbia University Medical Center

8:00–11:30AM

Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma

Matthew Ingham | NewYork-Presbyterian & Columbia University Medical Center

8:00–11:30AM

A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Kevin Kalinsky | NewYork-Presbyterian & Columbia University Medical Center

4:45-5:05 PM

Liquid and Solid Biopsies of Metastatic Lesions: How, When, and What to Do With the Results?

Himisha Beltran | NewYork-Presbyterian & Weill Cornell Medicine

Monday, June 5

8:00-11:30 AM

Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202)

and

Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102)

Morton Coleman | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

8:00-11:30 AM

The effect of supplemental estrogen on the outcomes of NSCLC patients in the SEER-Medicare database

Samuel Heilbroner | NewYork-Presbyterian & Columbia University Medical Center

8:00-11:30 AM

Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR)

Suzanne Lentzsch | NewYork-Presbyterian & Columbia University Medical Center

8:00-11:30 AM

Rates of peripheral neuropathy (PN) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal phase III trials

Ruben Niesvizky | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

8:00-11:30 AM

Innovative approach to determine overall survival (OS) benefit for orphan diseases using case match control analyses (CMCA): The PROPEL experience of pralatrexate in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL)

Owen O'Connor | NewYork-Presbyterian & Columbia University Medical Center

8:00-11:30 AM

Tyrosine Kinase Inhibitor therapy discontinuation in patients with CML in chronic phase: a US clinical practice perspective

Ellen Ritchie | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

8:00-11:30 AM

A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence: Updated results

Sheena Sahota | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

1:15-4:45 PM

Whole exome sequencing (WES) of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer (NEPC) informs tumor heterogeneity

Himisha Beltran | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

1:15-4:45 PM

Does race play a role in genetic screening for hereditary cancer syndromes?

Sudeshna Chatterjee | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

1:15–4:45 PM

Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC)

Charles Drake | NewYork-Presbyterian & Columbia University Medical Center

1:15-4:45 PM

Underutilization of multigene panels among Ashkenazi Jewish patients

Jessica Fields | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

1:15–4:45 PM

Financial assistance for fertility preservation at cancer diagnosis: An analysis of the LIVESTRONG Fertility program

Lenore Omesi | NewYork-Presbyterian & Columbia University Medical Center

1:15-4:45 PM

Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC)

Loredana Puca | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

1:15-4:45 PM

Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Scott Tagawa | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A

1:15-4:45 PM

Patterns of genetic screening for hereditary cancer syndromes: Effect of Supreme Court’s ruling invalidating single gene patent rights

Zhen Ni Zhou | NewYork-Presbyterian & Weill Cornell Medicine

Location: Hall A